At the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, gives us an update on the recent developments in FLT3 inhibitors for the treatment of acute myeloid leukemia (AML). Dr Perl explains how midostaurin, an older generation FLT3 inhibitor, has a relatively low potency. This has fueled the development of highly selective treatments, such as quizartinib and gilteritinib, which are highly potent and have increased selectivity to FLT3 mutations.
